LibbyP.The pathogenesis, prevention, and treatment of atherosclerosis. In: FauciA.S., BraunwaldE., KasperD.L. eds. Harrison's Principles of Internal Medicine.17th ed.New York, NY: McGraw-Hill; 2008: 1501–1509.
2.
RobinsonJ.G., SmithB., MaheshwariN., SchrottH.Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis.J Am Coll Cardiol.2005; 46(10): 1855–1862.
3.
GrundyS.M., CleemanJ.I., MerzC.N.B.Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.Circulation.2004; 110(2): 227–239.
4.
BaigentC., KeechA., KearneyP.M.and the Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins.Lancet.2005; 366(9493): 1267–1278.
5.
Heart Protection Study Collaborative Group.MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial.Lancet.2002; 360(9326): 7–22.
6.
CannonC.P., BraunwaldE., McCabeC.H.and the Pravastatin or Atorvastatin Evaluation and Infection Therapy—Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes.N Engl J Med.2004; 350(15): 1495–1504.
7.
RydénL., StandiE., BartnikM.Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD).Eur Heart J Suppl.2007; 9(suppl l): C3–C74.
8.
LaRosaJ.C., GrundyS.M., WatersD.D.the Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease.N Engl J Med.2005; 352(14): 1425–1435.
9.
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group.The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHATLLT).JAMA.2002; 288(23): 2998–3007.
10.
de LorgerilM., RenaudS., MamelleN.Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease.Lancet.1994; 343(8911): 1454–1459.
11.
BotsM.L., VisserenF.L., EvansG.W.and RADIANCE 2 Investigators. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial.Lancet.2007; 370(9582): 153–160.
12.
KasteleinJ.J., AkdimF., StroesE.S.for the ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia.N Engl J Med.2008; 358: 1431–1443.
13.
WhayneT.F.Jr.Is there a problem with ezetimibe or just ENHANCED hype?Angiology.2009; 59(6): 661–663.
14.
ToutouzasP., RichterD.Carotid intima-media thickness (cIMT): a useful clinic tool or research luxury? Another view of the ENHANCE trial.Angiology.2008; 59(2 suppl): 77S–79S.
